Know Cancer

forgot password

Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 3
18 Years
Open (Enrolling)
Carcinoma, Renal Cell

Thank you

Trial Information

Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

This study will evaluate the efficacy and safety of pazopanib compared to sunitinib in
subjects with advanced RCC who have received no prior systemic therapy for advanced or
metastatic RCC. Subjects will be randomized in a 1:1 ratio to receive either 800mg pazopanib
to be administered once daily orally continuous dosing or 50mg sunitinib to be administered
in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment. Subjects
are permitted to receive supportive care throughout the study including transfusion of blood
and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents,
analgesics, erythropoietin, or bisphosphonates, when appropriate. The study treatment will
continue until subjects experience disease progression, unacceptable toxicity, withdraw
consent, or death.

Inclusion Criteria:

- Written informed consent

- Diagnosis of renal cell carcinoma with clear-cell component histology.

- Received no prior systemic therapy (interleukin-2, interferon-alpha, chemotherapy,
bevacizumab, mTOR inhibitor, sunitinib, sorafenib or other VEGF TKI) for advanced or
metastatic RCC

- Locally advanced or metastatic renal cell carcinoma

- Measurable disease by CT or MRI

- Karnofsky performance scale status of >=70

- Age >=18 years

- A female is eligible to enter and participate in this study if she is of:
non-childbearing or agrees to use adequate contraception.

- Adequate organ system function

- Total serum calcium concentration <12.0mg/dL

- Left ventricular ejection fraction >= lower limit of institutional normal.

Exclusion Criteria:

- Pregnant or lactating female (unless agrees to refrain from nursing throughout the
treatment period and for 14 days following the last dose of study)

- History of another malignancy (unless have been disease-free for 3 years)

- History or clinical evidence of central nervous system (CNS) metastases (unless have
previously-treated CNS metastases and meet all 3 of the following criteria are: are
asymptomatic, have had no evidence of active CNS metastases for >=6 months prior to
enrolment, and have no requirement for steroids or enzyme-inducing anticonvulsants)

- Clinically significant gastrointestinal abnormalities including, but not limited to:
malabsorption syndrome, major resection of the stomach or small bowel that could
affect the absorption of study drug, active peptic ulcer disease, known intraluminal
metastatic lesion/s with suspected bleeding, Inflammatory bowel disease, ulcerative
colitis, or other gastrointestinal conditions with increased risk of perforation,
history of abdominal fistula, gastrointestinal perforation, or intra abdominal
abscess within 28 days prior to beginning study treatment.

- Presence of uncontrolled infection.

- Prolongation of corrected QT interval (QTc) > 480 milliseconds

- History of any one or more of the following cardiovascular conditions within the past
12 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina,
coronary artery by-pass graft surgery, symptomatic peripheral vascular disease, Class
III or IV congestive heart failure, as defined by the New York Heart Association

- History of cerebrovascular accident including transient ischemic attack within the
past 12 months

- History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the
past 6 months (unless had recent DVT and have been treated with therapeutic
anti-coagulating agents for at least 6 weeks)

- Poorly controlled hypertension (defined as systolic blood pressure of >=150mmHg or
diastolic blood pressure of >=90mmHg). Initiation or adjustment of antihypertensive
medication(s) is permitted prior to study entry

- Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
presence of any non-healing wound, fracture, or ulcer.

- Evidence of active bleeding or bleeding susceptibility

- Spitting/coughing up blood within 6 weeks of first dose of study drug

- Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels

- Any serious and/or unstable pre-existing medical, psychiatric, or other conditions
that could interfere with patient's safety, obtaining informed consent or compliance
to the study.

- Use any prohibited medications within 14 days of the first dose of study medication.

- Use of an investigational agent, including an investigational anti-cancer agent,
within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study

- Prior use of an investigational or licensed drug that targets VEGF or VEGF receptors
(eg. bevacizumab, sunitinib, sorafenib, etc), or are mTOR inhibitors (eg.
temsirolimus, everolimus, etc).

- Is now undergoing and/or has undergone in the 14 days immediately prior to first dose
of study drug, any cancer therapy (surgery, tumor embolization, chemotherapy,
radiation therapy, immunotherapy, biological therapy, or hormonal therapy)

- Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is
progressing in severity.

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to pazopanib or sunitinib.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free Survival (PFS)

Outcome Description:

PFS is defined as the interval between the date of randomization and the earliest date of progressive disease (PD), as defined by the Independent Review Committee (IRC), or death due to any cause. The IRC defined PD per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1. Per RECIST, PD is defined as a >=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of >=1 new lesion. The Kaplan-Meier method was used for PFS estimates.

Outcome Time Frame:

From randomization until the earliest date of disease progression or death (up to Study Week 191)

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:




Start Date:

August 2008

Completion Date:

December 2014

Related Keywords:

  • Carcinoma, Renal Cell
  • Locally advanced and/or metastatic renal cell carcinoma
  • Pazopanib
  • Sunitinib
  • GW786034
  • Renal cell carcinoma
  • Carcinoma
  • Carcinoma, Renal Cell



GSK Investigational Site Phoenix, Arizona  85013 - 4496
GSK Investigational Site Bakersfield, California  93309
GSK Investigational Site Gainesville, Florida  32610
GSK Investigational Site Indianapolis, Indiana  46260
GSK Investigational Site Lexington, Kentucky  40536-0098
GSK Investigational Site Springfield, Massachusetts  01107
GSK Investigational Site Duluth, Minnesota  55805
GSK Investigational Site St. Louis, Missouri  63141
GSK Investigational Site Raleigh, North Carolina  27609
GSK Investigational Site Akron, Ohio  44304
GSK Investigational Site Fort Worth, Texas  76104
GSK Investigational Site Savannah, Georgia  31405
GSK Investigational Site Park Ridge, Illinois  60068
GSK Investigational Site Bettendorf, Iowa  52722
GSK Investigational Site Baltimore, Maryland  21201
GSK Investigational Site Royal Oak, Michigan  48073
GSK Investigational Site Oklahoma City, Oklahoma  73112
GSK Investigational Site Pittsburgh, Pennsylvania  15213
GSK Investigational Site Columbia, South Carolina  29210
GSK Investigational Site Germantown, Tennessee  38138
GSK Investigational Site Salem, Virginia  24153
GSK Investigational Site New York, New York  10021
GSK Investigational Site Aurora, Colorado  80012
GSK Investigational Site Hartford, Connecticut  06106
GSK Investigational Site Washington, District of Columbia  20307-5001
GSK Investigational Site Hattiesburg, Mississippi  39401
GSK Investigational Site Omaha, Nebraska  68131
GSK Investigational Site Henderson, Nevada  89014
GSK Investigational Site Edison, New Jersey  08837
GSK Investigational Site Oregon City, Oregon  97045
GSK Investigational Site Seattle, Washington  98133